

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-14. (Cancelled)

15. (New) A pharmaceutical composition comprising lipids extracted from the mother of pearl from mother-of-pearl molluscs in a pharmaceutically acceptable support.

16. (New) The composition according to claim 15, wherein the mother-of-pearl molluscs are oysters.

17. (New) The composition according to claim 16, wherein oysters are oysters of the genus *Pinctada* and more particularly of the genus *Pinctada* species *margaritifera*.

18. (New) The composition according to claim 15, wherein the pharmaceutically acceptable support is an excipient suitable for topical, enteral or parenteral application.

19. (New) The composition according to claim 15, wherein the pharmaceutically acceptable support is an excipient suitable for topical application.

20. (New) The composition according to claim 15, wherein the lipids are present at a concentration comprised between 0.02% and 3% by weight, preferably between 0.25% and 2% by weight, and advantageously between 0.5% and 1%, relative to the total weight of the composition.

21. (New) The composition according to claim 15, for the treatment of pathologies involving a decrease in filaggrin activity and/or an increase in membrane transglutaminase activity.

22. (New) The composition according to claim 15, for the treatment of pathologies related to a decrease in cutaneous filaggrin activity and/or cutaneous overexpression of membrane transglutaminase.

23. (New) The composition according to claim 15, for the treatment of cutaneous pathologies, more particularly selected in the group consisting of psoriasis, ichthyosis and atopic dermatitis.

24. (New) The composition according to claim 15, for the treatment of autoimmune diseases related to an autoimmune reaction to filaggrin, in particular rheumatoid arthritis.

25. (New) The composition according to claim 15, wherein it further comprises at least one other therapeutically active ingredient for use that is simultaneous, separate or spread out over time.

26. (New) The composition according to claim 16, wherein the other therapeutically active ingredient is selected from corticosteroids, coal tar, anthralin, vitamin D3 and derivatives, and retinoids.

27. (New) A device comprising lipids such as defined in claim 15 and a physiologically acceptable excipient.

28. (New) The device according to claim 27, having a form which is suitable to subcutaneous or percutaneous injection, in particular in the form of a syringe or infusion.